,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,400 Oyster Point Boulevard,Suite 505,South San Francisco,CA,94080,United States,650 244 4990,650 244 4956,https://www.titanpharm.com,Biotechnology,Healthcare,"Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.",4,"{'maxAge': 1, 'name': 'Mr. David Elliot Lazar', 'age': 31, 'title': 'Principal Financial Officer, CEO & Interim Chairman', 'yearBorn': 1991, 'fiscalYear': 2022, 'totalPay': 726080, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.4651,0.4995,0.4602,0.504,0.4651,0.4995,0.4602,0.504,0.0,1.09993,-0.5537362,28915,28915,92103,24610,24610,0.4838,0.515,1800,4000,7566713,0.43,1.41,19.05973,0.5406,0.7609,0.0,0.0,USD,7591197,0.0,10809180,15016300,88552,362234,1690761600,1693440000,0.0058999998,0.27734,0.0962,3.06,0.0077,-0.069,1672444800,1703980800,1688083200,-8465000,-0.6,-0.91,1:30,1606780800,19.121,-0.959,NCM,EQUITY,TTNP,TTNP,"Titan Pharmaceuticals, Inc.","Titan Pharmaceuticals, Inc.",821975400,America/New_York,EDT,-14400000,0.5039,3.0,hold,105000,0.007,-7914000,128000,0.062,0.27,397000,0.027,-1.1689601,-3.6542199,-3496875,-6463000,-0.447,0.0,0.0,-21.508821,USD,
1,400 Oyster Point Boulevard,Suite 505,South San Francisco,CA,94080,United States,650 244 4990,650 244 4956,https://www.titanpharm.com,Biotechnology,Healthcare,"Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.",4,"{'maxAge': 1, 'name': 'Dr. Katherine L. Beebe-DeVarney Ph.D.', 'age': 61, 'title': 'Pres, COO & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 308000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.4651,0.4995,0.4602,0.504,0.4651,0.4995,0.4602,0.504,0.0,1.09993,-0.5537362,28915,28915,92103,24610,24610,0.4838,0.515,1800,4000,7566713,0.43,1.41,19.05973,0.5406,0.7609,0.0,0.0,USD,7591197,0.0,10809180,15016300,88552,362234,1690761600,1693440000,0.0058999998,0.27734,0.0962,3.06,0.0077,-0.069,1672444800,1703980800,1688083200,-8465000,-0.6,-0.91,1:30,1606780800,19.121,-0.959,NCM,EQUITY,TTNP,TTNP,"Titan Pharmaceuticals, Inc.","Titan Pharmaceuticals, Inc.",821975400,America/New_York,EDT,-14400000,0.5039,3.0,hold,105000,0.007,-7914000,128000,0.062,0.27,397000,0.027,-1.1689601,-3.6542199,-3496875,-6463000,-0.447,0.0,0.0,-21.508821,USD,
2,400 Oyster Point Boulevard,Suite 505,South San Francisco,CA,94080,United States,650 244 4990,650 244 4956,https://www.titanpharm.com,Biotechnology,Healthcare,"Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.",4,"{'maxAge': 1, 'name': 'Mr. Mike  Fritz', 'title': 'National Sales Director', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.4651,0.4995,0.4602,0.504,0.4651,0.4995,0.4602,0.504,0.0,1.09993,-0.5537362,28915,28915,92103,24610,24610,0.4838,0.515,1800,4000,7566713,0.43,1.41,19.05973,0.5406,0.7609,0.0,0.0,USD,7591197,0.0,10809180,15016300,88552,362234,1690761600,1693440000,0.0058999998,0.27734,0.0962,3.06,0.0077,-0.069,1672444800,1703980800,1688083200,-8465000,-0.6,-0.91,1:30,1606780800,19.121,-0.959,NCM,EQUITY,TTNP,TTNP,"Titan Pharmaceuticals, Inc.","Titan Pharmaceuticals, Inc.",821975400,America/New_York,EDT,-14400000,0.5039,3.0,hold,105000,0.007,-7914000,128000,0.062,0.27,397000,0.027,-1.1689601,-3.6542199,-3496875,-6463000,-0.447,0.0,0.0,-21.508821,USD,
3,400 Oyster Point Boulevard,Suite 505,South San Francisco,CA,94080,United States,650 244 4990,650 244 4956,https://www.titanpharm.com,Biotechnology,Healthcare,"Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.",4,"{'maxAge': 1, 'name': 'Jennifer  Kiernan', 'title': 'Exec. Assistant to CEO & Investor Communications Coordinator', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.4651,0.4995,0.4602,0.504,0.4651,0.4995,0.4602,0.504,0.0,1.09993,-0.5537362,28915,28915,92103,24610,24610,0.4838,0.515,1800,4000,7566713,0.43,1.41,19.05973,0.5406,0.7609,0.0,0.0,USD,7591197,0.0,10809180,15016300,88552,362234,1690761600,1693440000,0.0058999998,0.27734,0.0962,3.06,0.0077,-0.069,1672444800,1703980800,1688083200,-8465000,-0.6,-0.91,1:30,1606780800,19.121,-0.959,NCM,EQUITY,TTNP,TTNP,"Titan Pharmaceuticals, Inc.","Titan Pharmaceuticals, Inc.",821975400,America/New_York,EDT,-14400000,0.5039,3.0,hold,105000,0.007,-7914000,128000,0.062,0.27,397000,0.027,-1.1689601,-3.6542199,-3496875,-6463000,-0.447,0.0,0.0,-21.508821,USD,
4,400 Oyster Point Boulevard,Suite 505,South San Francisco,CA,94080,United States,650 244 4990,650 244 4956,https://www.titanpharm.com,Biotechnology,Healthcare,"Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.",4,"{'maxAge': 1, 'name': 'Joe  Schrei', 'title': 'Exec. Director of Commercial Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.4651,0.4995,0.4602,0.504,0.4651,0.4995,0.4602,0.504,0.0,1.09993,-0.5537362,28915,28915,92103,24610,24610,0.4838,0.515,1800,4000,7566713,0.43,1.41,19.05973,0.5406,0.7609,0.0,0.0,USD,7591197,0.0,10809180,15016300,88552,362234,1690761600,1693440000,0.0058999998,0.27734,0.0962,3.06,0.0077,-0.069,1672444800,1703980800,1688083200,-8465000,-0.6,-0.91,1:30,1606780800,19.121,-0.959,NCM,EQUITY,TTNP,TTNP,"Titan Pharmaceuticals, Inc.","Titan Pharmaceuticals, Inc.",821975400,America/New_York,EDT,-14400000,0.5039,3.0,hold,105000,0.007,-7914000,128000,0.062,0.27,397000,0.027,-1.1689601,-3.6542199,-3496875,-6463000,-0.447,0.0,0.0,-21.508821,USD,
